Skin Side Effects of BRAF and MEK Inhibitors in Melanoma Treatment
Author Information
Author(s): Qian Junhui, Wan Jinlong, Yao Qin, Chen Yin, Ling Tao, Zhang Yuejuan, Tang Zhihua
Primary Institution: Department of Pharmacy, Shaoxing People’s Hospital, Shaoxing, China
Hypothesis
What is the association of BRAF and MEK inhibitor treatment with cutaneous adverse events in patients with melanoma compared to BRAF inhibitor alone?
Conclusion
BRAF and MEK inhibitors are associated with a lower risk of skin side effects compared to BRAF inhibitors alone.
Supporting Evidence
- Patients treated with BRAF and MEK inhibitors had a lower risk of rash compared to those on BRAF inhibitors alone.
- 10.3% of patients on BRAF and MEK inhibitors developed alopecia, compared to 37.59% on BRAF inhibitors alone.
- The combination therapy showed a significant reduction in the incidence of hyperkeratosis compared to BRAF inhibitor monotherapy.
- BRAF inhibitor alone was associated with a 5.2-fold increase in the risk of cutaneous squamous-cell carcinoma.
Takeaway
This study found that using a combination of two cancer drugs, BRAF and MEK inhibitors, causes fewer skin problems than using just one drug.
Methodology
A systematic review and meta-analysis of randomized clinical trials comparing BRAF and MEK inhibitors with BRAF inhibitors alone.
Potential Biases
Potential bias from analyzing two studies as separate when they were part of the same trial.
Limitations
The study could not perfectly separate adverse events from BRAF inhibitors or MEK inhibitors due to the nature of the treatment regimens.
Participant Demographics
Adult patients with melanoma, with a mean age range of 54-57 years and varying male percentages across studies.
Statistical Information
P-Value
0.039
Confidence Interval
0.20–0.41
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website